Overall, current evidence indicates that, in the setting of BRCA1-defective tumors, HRD is an important therapeutic target in breast cancer, since it could be therapeutically exploited by the use of conventional drugs, including platinum agents [45,46,47] as well as PARPis, thus suggesting a relevant role of Alt-NHEJ in this disease. This evidence concerns the gene BRCA1 and breast carcinoma.